Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

Max Gelman

Senior Editor

CHICAGO — Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease drug was put on a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

Max Gelman

Senior Editor

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

DOGE set today as their last day at FDA. Instead, they're continuing to get full pay and don't work

Regeneron makes $80M obesity deal with Hansoh

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug